AGFG1 and Parkinson disease: Given that several LRKK2 variants increase LRKK2 kinase activity toward Rab10, an emerging new approach for disease modification in Parkinson’s disease is inhibition of the LRRK2-Rab signaling pathway and subsequently restoring normal membrane trafficking and lysosomal activity (Jennings et al., 2022).